Targeting the Tumor: GSK’s $10.6B Bet on Nuvalent
GSK’s biggest-ever acquisition adds two precision lung-cancer drugs to its pipeline.
TL;DR — GSK agreed to acquire Nuvalent for $10.6 billion ($124/share, a 40% premium) — its biggest deal to date — to add two late-stage targeted lung-cancer drugs, zidesamtinib (ROS1) and neladalkib (ALK), with FDA decisions due later in 2026.
On June 9, 2026, GSK paid up — $10.6 billion — for two drugs aimed at hard-to-treat lung cancers.
The deal
GSK agreed to acquire Nuvalent for $10.6 billion — $124.00 per share in cash, a 40% premium to the prior close — its biggest acquisition to date and third major deal of 2026. The prize is two late-stage targeted therapies for non-small cell lung cancer: zidesamtinib (a selective ROS1 inhibitor) and neladalkib (a selective ALK inhibitor), with FDA decision dates of Sept 18 and Nov 27, 2026.
| Detail | |
|---|---|
| Deal value | $10.6B ($124/share) |
| Premium | 40% |
| Lead assets | zidesamtinib (ROS1), neladalkib (ALK) |
| FDA dates | Sep 18 & Nov 27, 2026 |
What they said
"The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients." — Luke Miels, CEO, GSK
Why it matters
- Oncology firepower. GSK buys two near-market precision lung-cancer drugs.
- Two mutations, one deal. ROS1 and ALK are distinct NSCLC drivers, broadening reach.
- Big Pharma M&A continues. It positions GSK against Pfizer and Roche in targeted oncology.
FAQ
Why is GSK acquiring Nuvalent?
To strengthen its oncology pipeline. The $10.6 billion deal (announced June 9, 2026) adds two late-stage non-small cell lung-cancer drugs — zidesamtinib (a ROS1 inhibitor) and neladalkib (an ALK inhibitor) — with FDA decisions due September 18 and November 27, 2026.
How much is GSK paying, and is it a premium?
GSK is paying $10.6 billion, or $124.00 per Nuvalent share in cash — a 40% premium to the prior close and GSK’s biggest acquisition to date.
Sources
Image: “GSK headquarters, Brentford” by belemita, CC BY 3.0, via Wikimedia Commons.
← Back to all posts